Vanda Pharmaceuticals Partners with Monumental Sports for New Arena Studio

WASHINGTON, Oct. 8, 2025 — Vanda Pharmaceuticals, a leading global biopharmaceutical company headquartered in Washington, D.C., has been named the newest Founding Partner for Monumental Sports & Entertainment‘s next-generation arena in downtown Washington. This partnership includes exclusive entitlement to the Vanda Pharmaceuticals Studio within the Monumental Sports Network (MNMT).

The studio, which opened in March 2024, will serve as a hub for pre- and post-game coverage as well as original content spanning MSE’s sports portfolio, which includes the NBA’s Washington Wizards and NHL’s Washington Capitals. Vanda has become the second Founding Partner of Monumental’s transformation of Capital One Arena, following United Airlines.

“This is a bold, future-facing partnership,” said Ted Leonsis, CEO of Monumental Sports & Entertainment. “Vanda Pharmaceuticals is a hometown success story with a global footprint, and they will play a significant role in shaping our media future.”

The partnership is expected to enhance fan engagement through live events and community programs, providing branding visibility across MSE platforms. Vanda Pharmaceuticals CEO Mihael H. Polymeropoulos expressed pride in this local partnership, emphasizing its potential to foster growth and innovation in the D.C. community.

The Vanda Pharmaceuticals Studio is located in a state-of-the-art facility that features cutting-edge technology including 24 cameras and over 1,200 square feet of 4K LED displays. It is built to meet the demands of modern sports broadcasting and aims to connect with millions of fans each season.

As Phase One of the arena construction nears completion, the venue is expected to welcome approximately three million guests annually, enhancing the overall experience with high-tech features and immersive design.